Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood diseases
Biotech
Silence breaks down phase 1 data on blood disorder prospect
The polycythemia vera data provide an early look at how the siRNA prospect may match up to rivals from Incyte and Takeda.
Nick Paul Taylor
Jun 27, 2024 9:40am
Takeda's anti-CD38 antibody boosts platelet count in phase 2
Jun 24, 2024 8:58am
Takeda plays Protagonist, paying $300M for blood disease pact
Jan 31, 2024 5:41pm
ASH: Pfizer swims in crowded sickle cell, hemophilia waters
Dec 9, 2023 7:00pm
Sickle cell gene therapy process may cause cancerous mutations
Nov 20, 2023 9:10am
One shot to cure sickle cell? Scientists give it a try with mRNA
Jul 28, 2023 11:12am
